Shelf life (days): 1460.0
Formulation: A solid
Formal Name: 6-(4-(1-(cyclohexyl-2,2,6,6-d4)-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one
Purity: ≥99% deuterated forms (d1-d4)
Formula Markup: C20H23D4N5O2
Formula Weight: 373.48512
CAS Number: 1215541-47-1
Notes: Cilostazol-d4 is intended for use as an internal standard for the quantification of cilostazol (Item No. 15035) by GC- or LC-MS. Cilostazol is a phosphodiesterase 3A (PDE3A) inhibitor (IC50 = 0.2 µM for the platelet enzyme).{54486} It is selective for PDE3A over PDE1, -2, -4, and 5 (IC50s = >5 µM for all). Cilostazol inhibits collagen- or ADP-induced aggregation of isolated rabbit platelets (IC50s = 29 and 31 µM, respectively).{23681} In vivo, cilostazol (30 mg/kg) reduces thrombus formation by 84% in a mouse model of pulmonary thromboembolism. It reduces cardiac fibrosis and prevents the development of diastolic dysfunction and cardiac hypertrophy induced by a high-fat diet and angiotensin II in mice.{54485} Formulations containing cilostazol have been used in the treatment of the symptoms of intermittent claudication in peripheral vascular disease.
English
Deutsch
